Y
Yu Zhou
Publications - 2
Citations - 90
Yu Zhou is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Mucosal melanoma. The author has an hindex of 1, co-authored 1 publications receiving 40 citations.
Papers
More filters
Journal ArticleDOI
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).
Lu Si,Xiaoshi Zhang,Yongqian Shu,Hongming Pan,Di Wu,Jiwei Liu,Fang Lou,Lili Mao,Xuan Wang,Xizhi Wen,Yanhong Gu,Lingjun Zhu,Shijie Lan,Xin Cai,Scott J. Diede,Yu Zhou,Jun Ge,Jianfeng Li,Haiyan Wu,Jun Guo +19 more
TL;DR: Pembrolizumab was well tolerated and provided clinically meaningful antitumor activity as second-line therapy in Chinese patients with advanced melanoma and two deaths occurred that were unrelated to treatment.
Journal ArticleDOI
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial
Shukui Qin,Zhendong Chen,Weijia Fang,Zhenggang Ren,Ruocai Xu,Baek-Yeol Ryoo,Zhiqiang Meng,Y. Bai,Xiaoming Chen,Xiu-Feng Liu,Juxiang Xiao,Gwo Fuang Ho,Yimin Mao,Xin Wang,Jieer Ying,Jianfeng Li,Wenyan Zhong,Yu Zhou,Abby B. Siegel,Chunyi Hao +19 more
TL;DR: In a double-blind, phase III trial, 453 patients with advanced hepatocellular carcinoma (HCC) and progression during or after treatment with or intolerance to sorafenib or oxaliplatin-based chemotherapy were randomly assigned in a 2:1 ratio to receive pembrolizumab (200 mg) or placebo once every 3 weeks for ≤ 35 cycles plus best supportive care as mentioned in this paper .